Literature DB >> 28451724

Chronic loss of inhibitor-1 diminishes cardiac RyR2 phosphorylation despite exaggerated CaMKII activity.

Stefan Neef1, Jordi Heijman2, Kristian Otte3, Matthias Dewenter3,4, Ali R Saadatmand3,4, Stefanie Meyer-Roxlau3, Christopher L Antos3, Johannes Backs4, Dobromir Dobrev5, Michael Wagner3, Lars S Maier1, Ali El-Armouche6.   

Abstract

Inhibitor-1 (I-1) modulates protein phosphatase 1 (PP1) activity and thereby counteracts the phosphorylation by kinases. I-1 is downregulated and deactivated in failing hearts, but whether its role is beneficial or detrimental remains controversial, and opposing therapeutic strategies have been proposed. Overactivity of Ca2+/calmodulin-dependent protein kinase II (CaMKII) with hyperphosphorylation of ryanodine receptors (RyR2) at the CaMKII-site is recognized to be central for heart failure and arrhythmias. Using an I-1-deficient mouse line as well as transfected cell lines, we investigated the effects of acute and chronic modulation of I-1 on CaMKII activity and RyR2 phosphorylation. We demonstrate that I-1 acutely modulates CaMKII by regulating PP1 activity. However, while ablation of I-1 should thus limit CaMKII-activation, we unexpectedly found exaggerated CaMKII-activation under β-adrenergic stress upon chronic loss of I-1 in knockout mice. We unraveled that this is due to chronic upregulation of the exchange protein activated by cAMP (EPAC) leading to augmented CaMKII activation, and using computational modeling validated that an increase in EPAC expression can indeed explain our experimental findings. Interestingly, at the level of RyR2, the increase in PP1 activity more than outweighed the increase in CaMKII activity, resulting in reduced RyR phosphorylation at Ser-2814. Exaggerated CaMKII activation due to counterregulatory mechanisms upon loss of I-1 is an important caveat with respect to suggested therapeutic I-1-inhibition, as CaMKII overactivity has been heavily implicated in several cardiac pathologies.

Entities:  

Keywords:  Ca2+/calmodulin-dependent protein kinase II; Inhibitor-1; Protein phosphatase 1; Ryanodine receptor

Mesh:

Substances:

Year:  2017        PMID: 28451724     DOI: 10.1007/s00210-017-1376-1

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  18 in total

1.  Type 1 phosphatase, a negative regulator of cardiac function.

Authors:  Andrew N Carr; Albrecht G Schmidt; Yoichi Suzuki; Federica del Monte; Yoji Sato; Carita Lanner; Kristine Breeden; Shao-Ling Jing; Patrick B Allen; Paul Greengard; Atsuko Yatani; Brian D Hoit; Ingrid L Grupp; Roger J Hajjar; Anna A DePaoli-Roach; Evangelia G Kranias
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

Review 2.  CaMKII in myocardial hypertrophy and heart failure.

Authors:  Mark E Anderson; Joan Heller Brown; Donald M Bers
Journal:  J Mol Cell Cardiol       Date:  2011-01-27       Impact factor: 5.000

3.  Protein phosphatase-1 regulation in the induction of long-term potentiation: heterogeneous molecular mechanisms.

Authors:  P B Allen; O Hvalby; V Jensen; M L Errington; M Ramsay; F A Chaudhry; T V Bliss; J Storm-Mathisen; R G Morris; P Andersen; P Greengard
Journal:  J Neurosci       Date:  2000-05-15       Impact factor: 6.167

Review 4.  CaMKII as a target for arrhythmia suppression.

Authors:  Julian Mustroph; Stefan Neef; Lars S Maier
Journal:  Pharmacol Ther       Date:  2016-10-11       Impact factor: 12.310

5.  Role of calcineurin and protein phosphatase-2A in the regulation of phosphatase inhibitor-1 in cardiac myocytes.

Authors:  Ali El-Armouche; Anna Bednorz; Torsten Pamminger; Diana Ditz; Michael Didié; Dobromir Dobrev; Thomas Eschenhagen
Journal:  Biochem Biophys Res Commun       Date:  2006-06-06       Impact factor: 3.575

6.  CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy.

Authors:  Johannes Backs; Kunhua Song; Svetlana Bezprozvannaya; Shurong Chang; Eric N Olson
Journal:  J Clin Invest       Date:  2006-06-08       Impact factor: 14.808

Review 7.  Epac in cardiac calcium signaling.

Authors:  Gema Ruiz-Hurtado; Eric Morel; Alejandro Domínguez-Rodríguez; Anna Llach; Frank Lezoualc'h; Jean-Pierre Benitah; Ana M Gomez
Journal:  J Mol Cell Cardiol       Date:  2012-12-07       Impact factor: 5.000

8.  Evidence for protein phosphatase inhibitor-1 playing an amplifier role in beta-adrenergic signaling in cardiac myocytes.

Authors:  Ali El-Armouche; Thomas Rau; Oliver Zolk; Diana Ditz; Torsten Pamminger; Wolfram-H Zimmermann; Elmar Jäckel; Sian E Harding; Peter Boknik; Joachim Neumann; Thomas Eschenhagen
Journal:  FASEB J       Date:  2003-01-02       Impact factor: 5.191

Review 9.  Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiology.

Authors:  Persoulla Nicolaou; Roger J Hajjar; Evangelia G Kranias
Journal:  J Mol Cell Cardiol       Date:  2009-05-27       Impact factor: 5.000

10.  Active inhibitor-1 maintains protein hyper-phosphorylation in aging hearts and halts remodeling in failing hearts.

Authors:  Tracy J Pritchard; Yoshiaki Kawase; Kobra Haghighi; Ahmad Anjak; Wenfeng Cai; Min Jiang; Persoulla Nicolaou; George Pylar; Ioannis Karakikes; Kleopatra Rapti; Jack Rubinstein; Roger J Hajjar; Evangelia G Kranias
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

View more
  4 in total

Review 1.  Molecular Basis of Atrial Fibrillation Pathophysiology and Therapy: A Translational Perspective.

Authors:  Stanley Nattel; Jordi Heijman; Liping Zhou; Dobromir Dobrev
Journal:  Circ Res       Date:  2020-06-18       Impact factor: 17.367

Review 2.  Functions and therapeutic potential of protein phosphatase 1: Insights from mouse genetics.

Authors:  Mónica Ferreira; Monique Beullens; Mathieu Bollen; Aleyde Van Eynde
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2018-07-26       Impact factor: 4.739

Review 3.  Stress-driven cardiac calcium mishandling via a kinase-to-kinase crosstalk.

Authors:  Charia McKee; Dan J Bare; Xun Ai
Journal:  Pflugers Arch       Date:  2021-02-15       Impact factor: 3.657

4.  Cellular Mechanisms of the Anti-Arrhythmic Effect of Cardiac PDE2 Overexpression.

Authors:  Michael Wagner; Mirna S Sadek; Nataliya Dybkova; Fleur E Mason; Johann Klehr; Rebecca Firneburg; Eleder Cachorro; Kurt Richter; Erik Klapproth; Stephan R Kuenzel; Kristina Lorenz; Jordi Heijman; Dobromir Dobrev; Ali El-Armouche; Samuel Sossalla; Susanne Kämmerer
Journal:  Int J Mol Sci       Date:  2021-05-01       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.